Zurich Insurance Group Ltd FI Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zurich Insurance Group Ltd FI reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 62.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,784 shares of the biopharmaceutical company’s stock after selling 39,857 shares during the period. Zurich Insurance Group Ltd FI’s holdings in Regeneron Pharmaceuticals were worth $16,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. OLD Second National Bank of Aurora grew its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 15 shares during the last quarter. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 15 shares during the period. Manchester Capital Management LLC grew its position in Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 18 shares during the period. Finally, Financial Perspectives Inc increased its holdings in Regeneron Pharmaceuticals by 10.9% during the fourth quarter. Financial Perspectives Inc now owns 193 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 19 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Citigroup raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $600.00 to $700.00 in a research report on Wednesday, May 14th. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research report on Wednesday, April 30th. StockNews.com lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. BMO Capital Markets decreased their price objective on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $695.00 price objective on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $890.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $614.79 on Wednesday. The firm has a market cap of $66.38 billion, a price-to-earnings ratio of 16.06, a P/E/G ratio of 2.34 and a beta of 0.43. The firm has a fifty day moving average price of $596.79 and a 200 day moving average price of $679.72. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the previous year, the firm earned $9.55 EPS. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.57%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.